跳至主要内容
临床试验/NCT05474781
NCT05474781招募中不适用

Micro-elimination of HCV Infection Among People Who Use Drug (PWUD) in British.Columbia: A Comprehensive, Multidisciplinary, Scalable Programmatic Approach

Vancouver Infectious Diseases Centre1 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2019年2月22日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
300
试验地点
1
主要终点
The proportion of individuals enrolled in the study who initiate HCV treatment

研究概览

简要总结

Identify 300 PWUD with chronic, viremic HCV infection and engage them in a multidisciplinary, generalizable model of care and initiate HCV treatment

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Ability to review, sign and date the IRB/IEC approved informed consent form
  • Age ≥19 years
  • Documented HCV RNA positive for 6 months or more, with any HCV genotype
  • Active PWUD (ongoing drug use or documented use within the previous 6 months) OR active enrolment in an opiate substitution program

排除标准

  • Previous DAA-based HCV treatment
  • Pregnant or breast-feeding
  • Indications of decompensated liver disease
  • Diagnosis of active hepatocellular carcinoma
  • Positive test at the time of screening for hepatitis B surface antigen (HBsAg)
  • Frequent injecting drug use that is judged by the treating physician to compromise subsequent HCV treatment safety
  • Inability or unwillingness to provide informed consent or to actively engage in care leading to the initiation of HCV treatment

结局指标

主要结局

The proportion of individuals enrolled in the study who initiate HCV treatment

时间窗: 60 months

次要结局

  • The proportion of individuals enrolled in the study who achieve sustained virologic response(72 months)

研究者

发起方
Vancouver Infectious Diseases Centre
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Eliminating HCV Infection Among PWUD | 临床试验